Anuncia Medical, Inc. Honored with an AZBio Fast Lane Award

Relieving Pressure on the Brain

Cerebrospinal fluid (CSF) normally flows through the cavities (ventricles) of our brains and bathes our brain and spinal column. Hydrocephalus is a condition caused by a buildup of this fluid deep within the brain. The excess fluid puts pressure on the brain. This pressure can damage brain tissues and cause a range of brain function problems. Hydrocephalus can happen at any age, but it occurs more frequently among infants and adults 60 and over.Continue reading

Dr. Brinton Named AZ Bioscience Researcher of the Year

Photo of Roberta Diaz Brinton, PhD

Roberta Diaz Brinton, PhD

Roberta Diaz Brinton, PhD, director of the University of Arizona Center for Innovation in Brain Science(CIBS) will be honored as the Arizona Bioscience Researcher of the Year by the Arizona Bioindustry Association (AZBio) at the 2022 AZBio Awards event Sept. 28 at the Phoenix Convention Center.

Dr. Brinton is a Regents Professor of Pharmacology with an additional appointment in neurology in the UArizona College of Medicine – Tucson and a member of BIO5 Institute. She returned to her alma mater in 2016 to create CIBS, a hybrid university/biotech research center designed to advance cures for Alzheimer’s disease, Parkinson’s disease, multiple sclerosis and amyotrophic lateral sclerosis, or ALS, through integrated discovery, translational and clinical science. Since its inception, CIBS has received more than $112 million in grants to advance cures for these neurodegenerative diseases.Continue reading

Aqualung Therapeutics Corp. Announces FDA Clearance of Investigational New Drug (IND) Application for ALT-100, a Novel mAb Therapy for the Treatment of Acute Respiratory Distress Syndrome (ARDS)

– Aqualung will continue the P1A Healthy Human Volunteer Trial and complete the trial first half of 2023
– The Phase 2A study (PUERTA) will be initiated in the 2nd half of 2023
– ALT-100 is the first humanized mAb therapy that targets the eNAMPT protein which plays a pivotal role in regulating inflammation and fibrosisContinue reading

Phoenix Mayor Kate Gallego honored with AZBio Public Service Award

The path for a cure for cancer will run through Phoenix.

Sit down with Phoenix Mayor Kate Gallego and bring up the subject of biosciences, you will experience a burst of energy and insight about the innovation in healthcare taking place across Phoenix, including the growth of businesses creating jobs, and a personal passion that, “the path for a cure for cancer will run through Phoenix.”Continue reading

Exact Sciences Awards Grants To Federally Qualified Health Centers Focused On Improving Colorectal Cancer Screening Of Vulnerable Populations

MADISON, Wis.Sept. 22, 2022 — Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, today awarded $525,000 in grants to eight federally qualified health centers focused on improving colorectal cancer screening rates in vulnerable populations.Continue reading

Vidium Animal Health® SearchLight DNA® Added to Antech Diagnostics® Portfolio of Tests Expanding Veterinarians’ Ability to Diagnose and Treat Cancer in Dogs

PHOENIX—September 22, 2022Vidium Animal Health announced today that it has entered a reseller agreement with Antech Diagnostics to provide SearchLight DNA, the best-in-class genomic diagnostic for cancer in dogs, to Antech’s large North American customer base. Genomic diagnostics in general, and SearchLight DNA in particular, are a key part of expanding the use of personalized medicine in canine patients.
Continue reading

Aqualung Therapeutics Corp. Awarded $4.8M Dollars From National Institute of Health (NIH) To Develop the ALT-100 Monoclonal Antibody for Pulmonary Arterial Hypertension and Inflammatory Bowel Disease

TUCSON, AZ / ACCESSWIRE / September 21, 2022 / Aqualung Therapeutics, an immunotherapeutics biotech company with an anti-inflammatory and anti-fibrosis therapeutic platform for serious unchecked inflammatory and fibrotic disorders, has been awarded two 3-year NIH FAST-TRACK AWARDS [R42DK135208; R42HL160422) to support development of ALT-100, a humanized monoclonal antibody (mAb) therapy for the chronic indications of Pulmonary Arterial Hypertension (PAH) and Inflammatory Bowel Disease (IBD). The ALT-100 mAb targets the inflammation-inducing damage-associated molecular pattern protein eNAMPT, and is currently in Phase 1A human safety trials.

Continue reading